Health · Medical Research · 1 hr ago

Daraxonrasib combination shows early promise in pancreatic cancer trial

Daraxonrasib combination shows early promise in pancreatic cancer trial

A daraxonrasib combination is showing early promise in a trial involving people with pancreatic cancer.

The drug is a KRAS inhibitor that targets certain mutations called RAS, which drive tumour growth in most pancreatic cancers.

A doctor involved in the trial said researchers are seeing more tumour responses, deeper responses and nearly twice as long a period of disease control.

The results may point to longer survival, but they do not yet establish that patients will live longer.

Pancreatic cancer is diagnosed in about 11,500 people in Britain each year, and around 10,200 die from it, according to Cancer Research UK.

Researchers say longer trials are vital because tumours can return even when scans show no sign of cancer.

The drug may also be relevant to other cancers with similar mutations, but its effects there remain uncertain.

1 source

Related

What people are saying

Dr Wungki ParkTrial researcher at Memorial Sloan Kettering Cancer Center
We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.
via BBC
Prof Elena GarraldaChair of the EORTC cancer conference
These results are exciting because they show the combined treatment could potentially significantly improve patients' overall survival, as well as the time before tumours start to grow again.
via BBC
Dr GodfreyRole not stated
I would hope that the early success that we are beginning to see in pancreatic cancer can also be rolled out to other cancers.
via BBC
Cancer can come back and even if scans show there is no sign of it, you don't necessarily know you are cancer-free until more time has passed.
via BBC